Rapid Detection and Quantification of Selected Microsomal Substrates and Metabolites Using the Waters ACQUITY UPLC I-Class System and Xevo TQ-S micro

Importance of the Topic

The rapid assessment of drug metabolism and potential drug–drug interactions (DDIs) is critical in the early stages of pharmaceutical development. High-throughput ADME screening using liver microsomal incubations with cytochrome P450 enzymes provides essential data on compound stability, metabolic pathways, and DDI risk.

Study Aims and Overview

This study details the development and validation of a fast, sensitive LC-MS/MS method for the simultaneous detection and quantification of multiple CYP450 substrates and their metabolites. The method leverages the Waters ACQUITY UPLC I-Class System coupled with the Xevo TQ-S micro mass spectrometer.

Methodology and Instrumentation

Key components and conditions:

• Chromatography: ACQUITY UPLC I-Class with BEH C18 column (3.0×50 mm, 1.7 µm), 35 °C, 0.6 mL/min flow, 5 µL injection, gradient from 1% to 90% methanol over 2 min.
• Mobile Phases: A = 2 mM ammonium acetate/0.1% ammonium hydroxide in water; B = 2 mM ammonium acetate/0.1% ammonium hydroxide in methanol.
• Mass Spectrometry: Xevo TQ-S micro in positive ESI mode, MRM acquisition with polarity switching, capillary voltage 1 kV, dwell times 5 ms, cone voltages and collision energies optimized per analyte.
• Data Handling: MassLynx and TargetLynx software for peak integration, calibration, and quality control.

Key Results and Discussion

• Chromatographic separation achieved eight analytes with ~3 s peak widths under generic gradient conditions.
• Calibration linearity across >3 orders of magnitude with R² values ≥0.993; LLOQ of 0.2 nM with >14× signal-to-noise.
• Accuracy and precision within USFDA criteria (±15% accuracy, ≤15% CV) over the 0.2–5000 nM range.
• High acquisition speed enabled >20 data points per peak despite narrow UPLC peaks.
• RADAR mode demonstrated concurrent full-scan and MRM acquisition, facilitating detection of co-eluting matrix components and supporting method robustness.

Benefits and Practical Applications

This method consolidates multiple discrete assays into a single run, reducing cycle time and increasing throughput. Its sensitivity and broad dynamic range support low-level metabolite quantification. The approach aids early DDI risk assessment and streamlines ADME workflows in pharmaceutical discovery.

Future Trends and Applications

• Expanded use of simultaneous full-scan/MRM data for stability and metabolite profiling.
• Further automation and miniaturization for ultra-high-throughput screening.
• Integration with predictive software and AI for rapid data interpretation.
• Extension to additional CYP isoforms and broader biochemical matrices.

Conclusion

The combination of sub-2 µm UPLC separation and the Xevo TQ-S micro’s MRM and RADAR capabilities yields a rapid, sensitive, and robust platform for multiplexed microsomal substrate and metabolite analysis, meeting stringent regulatory validation criteria.

References

• Plumb R., Potts W., Rainville P., Alden P., Shave D., Baynham G., Mazzeo J. Addressing the analytical throughput challenges in ADME screening using rapid ultra-performance liquid chromatography/tandem mass spectrometry methodologies. Rapid Commun Mass Spectrom. 2008;22(14):2139–2152.
• Alden P., Plumb R., Jones M., Rainville P., Shave D. A rapid ultra-performance liquid chromatography/tandem mass spectrometric methodology for the in vitro analysis of pooled and cocktail cytochrome P450 assays. Rapid Commun Mass Spectrom. 2010;24(1):147–154.
• US FDA. Guidance for Industry: Bioanalytical Method Validation. May 2001.